person · Reporting owner
Fitzgerald Joseph Michael
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | EVP & Group Pres, Cardiology | July 31, 2026 | August 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BOSTON SCIENTIFIC CORP
Report date July 31, 2026 · Filed August 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) | 64,198 |
Reported balance
After 2026-07-31 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-07-31 · Other · Acquired 64,198 · Balance 64,198 F1: Acquistion made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock. F2: Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan. |
| Common StockSEC Table I · non-derivative | Direct | 213,907 |
Reported balance
Holding disclosure · report date 2026-07-31 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 213,907 |
| Common StockSEC Table I · non-derivative | IndirectBy Child | 5,234 |
Reported balance
Holding disclosure · report date 2026-07-31 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 5,234 F3: The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Acquistion made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock.
F2: Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan.
F3: The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2025 Filed Feb 18, 2025 22:52 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 3,960 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001870 · doc4.xml · nonDerivative · entry 3 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,078 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:52 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 4,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001870 · doc4.xml · derivative · entry 10 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,725 Underlying: Common Stock · 4,362 shares Expires 2027-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:52 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,990 | $106.11 | $211,158.90 |
DisclosureSEC source: 0001225208-25-001870 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,118 Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 22:52 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 4,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001870 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:52 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 28,789 | $0.00 Strike: $106.14 | $0.00 |
DisclosureSEC source: 0001225208-25-001870 · doc4.xml · derivative · entry 9 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,789 Underlying: Common Stock · 28,789 shares Expires 2035-02-13 F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 22:52 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantRestricted Stock Units · Derivative | 11,188 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001870 · doc4.xml · derivative · entry 8 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,188 Underlying: Common Stock · 11,188 shares Expires 2029-02-13 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:29 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 3,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001791 · doc4.xml · derivative · entry 4 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,386 Underlying: Common Stock · 3,462 shares Expires 2028-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:29 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,579 | $105.77 | $167,010.83 |
DisclosureSEC source: 0001225208-25-001791 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,746 Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 22:29 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 3,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001791 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,325 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 21:32 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 14,447 | $105.98 | $1,531,093.06 |
DisclosureSEC source: 0001225208-25-001683 · doc4.xml · nonDerivative · entry 4 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 172,863 Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 21:32 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 31,680 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-001683 · doc4.xml · nonDerivative · entry 3 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,310 F2 · kind: On February 16, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2024 and subject to the completion of the concurrent three-year individual service period. On February 11, 2025, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:32 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionPerformance Share Units · Derivative | 13,907 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-000204 · doc4.xml · derivative · entry 4 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,907 shares Expires 2024-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each performance shares unit represents the Company's commitment to issue one share of Boston Scientific common stock. F1 · shares: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024. F1 · derivative.exercise_date: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024. F1 · derivative.expiration_date: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:32 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 6,425 | $89.32 | $573,881.00 |
DisclosureSEC source: 0001225208-25-000204 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,600 Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:32 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 13,907 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-000204 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,025 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024. Read SEC document |
| December 10, 2024 Filed Feb 13, 2025 21:32 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 20 | $89.97 | $1,799.44 |
DisclosureSEC source: 0001225208-25-001683 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,148 F1 · kind: This transaction was inadvertently effected by a broker through a broker managed account, without any instruction from or knowledge of the reporting person. Read SEC document |
| December 03, 2024 Filed Feb 13, 2025 21:32 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | PurchaseCommon Stock | 50 | $90.29 | $4,514.60 |
DisclosureSEC source: 0001225208-25-001683 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,168 F1 · kind: This transaction was inadvertently effected by a broker through a broker managed account, without any instruction from or knowledge of the reporting person. Read SEC document |
| November 26, 2024 Filed Nov 26, 2024 21:41 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GiftCommon Stock | 11,236 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-010220 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,118 Read SEC document |
| November 25, 2024 Filed Nov 26, 2024 21:41 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GiftCommon Stock | 1,113 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-010220 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 159,354 Read SEC document |
| October 07, 2024 Filed Oct 8, 2024 21:48 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 57,618 | $0.00 Strike: $24.98 | $0.00 |
DisclosureSEC source: 0001225208-24-009233 · doc4.xml · derivative · entry 6 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 57,618 shares Expires 2027-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on May 23, 2024. F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant. Read SEC document |
| October 07, 2024 Filed Oct 8, 2024 21:48 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 59,021 | $0.00 Strike: $17.26 | $0.00 |
DisclosureSEC source: 0001225208-24-009233 · doc4.xml · derivative · entry 5 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 59,021 shares Expires 2026-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on May 23, 2024. F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| October 07, 2024 Filed Oct 8, 2024 21:48 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 132,527 | $85.00 | $11,264,887.77 |
DisclosureSEC source: 0001225208-24-009233 · doc4.xml · nonDerivative · entry 3 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 160,467 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on May 23, 2024. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $85.00 to $85.01, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 07, 2024 Filed Oct 8, 2024 21:48 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 57,618 | $24.98 | $1,439,297.64 |
DisclosureSEC source: 0001225208-24-009233 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 292,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on May 23, 2024. Read SEC document |
| October 07, 2024 Filed Oct 8, 2024 21:48 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 59,021 | $17.26 | $1,018,702.46 |
DisclosureSEC source: 0001225208-24-009233 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 235,376 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on May 23, 2024. Read SEC document |
| August 28, 2024 Filed Aug 29, 2024 20:13 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 14,132 | $80.00 | $1,130,560.00 |
DisclosureSEC source: 0001225208-24-008301 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 176,355 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on May 23, 2024. Read SEC document |
| May 13, 2024 Filed May 14, 2024 20:55 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GiftCommon Stock | 2,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-006005 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,487 Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 21:19 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | OtherCommon Stock | 67,974 | $66.22 | $4,501,238.28 |
DisclosureSEC source: 0001225208-24-002706 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Indirect · By 401(k) Disclosed balance after: 0 F1 · kind: Disposition made pursuant to an election by the reporting person to rebalance their holdings under the Company's 401(k) Retirement Savings Plan, which resulted in a discretionary transaction in shares of the Company's common stock. F2 · shares: Balance reflects the most current data available with regard to share holdings in the Company's 401(k) Retirement Savings Plan prior to the rebalance election by the reporting person. Read SEC document |
| February 18, 2024 Filed Feb 21, 2024 02:03 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 3,706 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002575 · doc4.xml · derivative · entry 11 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,706 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue on share of Boston Scientific common stock. F7 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. F7 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant. Read SEC document |
| February 18, 2024 Filed Feb 21, 2024 02:03 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,829 | $65.82 | $120,384.78 |
DisclosureSEC source: 0001225208-24-002575 · doc4.xml · nonDerivative · entry 6 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,867 Read SEC document |
| February 18, 2024 Filed Feb 21, 2024 02:03 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 3,706 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002575 · doc4.xml · nonDerivative · entry 5 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,696 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each deferred stock unit represents the Company's commitment to issue on share of Boston Scientific common stock. Read SEC document |
| February 17, 2024 Filed Feb 21, 2024 02:03 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 4,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002575 · doc4.xml · derivative · entry 10 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,167 Underlying: Common Stock · 4,167 shares Expires 2025-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F6 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F6 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2024 Filed Feb 21, 2024 02:03 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 2,057 | $65.82 | $135,391.74 |
DisclosureSEC source: 0001225208-24-002575 · doc4.xml · nonDerivative · entry 4 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,990 Read SEC document |
| February 17, 2024 Filed Feb 21, 2024 02:03 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 4,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002575 · doc4.xml · nonDerivative · entry 3 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,047 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 02:03 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 3,960 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002575 · doc4.xml · derivative · entry 9 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,920 Underlying: Common Stock · 3,960 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 02:03 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,806 | $65.82 | $118,870.92 |
DisclosureSEC source: 0001225208-24-002575 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,880 Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 02:03 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 3,960 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002575 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,686 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:21 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 4,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002304 · doc4.xml · derivative · entry 5 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,087 Underlying: Common Stock · 4,362 shares Expires 2027-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:21 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,990 | $65.95 | $131,240.50 |
DisclosureSEC source: 0001225208-24-002304 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,726 Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:21 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 4,362 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002304 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:21 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 36,509 | $0.00 Strike: $64.99 | $0.00 |
DisclosureSEC source: 0001225208-24-002042 · doc4.xml · derivative · entry 5 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,509 Underlying: Common Stock · 36,509 shares Expires 2034-02-12 F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:21 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantRestricted Stock Units · Derivative | 13,848 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002042 · doc4.xml · derivative · entry 4 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,848 Underlying: Common Stock · 13,848 shares Expires 2028-02-12 F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:21 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GiftCommon Stock | 550 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002042 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Indirect · By Child Disclosed balance after: 4,894 F1 · balance_after: The reporting person disclaims beneficial ownership of the shares held by his child, and this report should not be deemed an admission that the reporting person is the beneficial owner of his child's shares for purposes of Section 16 or for any other purpose. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:21 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GiftCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002042 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,354 Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:36 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 16,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-001779 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,354 Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:36 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantCommon Stock | 33,332 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-001779 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,804 F1 · kind: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2023 and subject to the completion of the concurrent three-year individual service period. On February 6, 2024, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Read SEC document |
| January 12, 2024 Filed Jan 16, 2024 21:39 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 11,660 | $60.00 | $699,600.00 |
DisclosureSEC source: 0001225208-24-000922 · doc4.xml · nonDerivative · entry 1 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,472 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 15, 2023, intended to comply with the prior version of Rule 10b5-1(c). Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 01:30 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionPerformance Share Units · Derivative | 21,799 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-000107 · doc4.xml · derivative · entry 8 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,799 shares Expires 2023-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each performance shares unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · shares: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2023. F2 · derivative.exercise_date: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2023. F2 · derivative.expiration_date: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2023. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 01:30 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 10,908 | $57.81 | $630,591.48 |
DisclosureSEC source: 0001225208-24-000107 · doc4.xml · nonDerivative · entry 4 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,132 Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 01:30 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 21,799 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-000107 · doc4.xml · nonDerivative · entry 3 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2023. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 01:30 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionStock Option (Right to Buy) · Derivative | 58,189 | $0.00 Strike: $16.31 | $0.00 |
DisclosureSEC source: 0001225208-24-000107 · doc4.xml · derivative · entry 7 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 58,189 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 15, 2023, intended to comply with the prior version of Rule 10b5-1(c). F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 01:30 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | SaleCommon Stock | 81,940 | $57.50 | $4,711,550.00 |
DisclosureSEC source: 0001225208-24-000107 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Group Pres, Cardiology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,241 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on February 15, 2023, intended to comply with the prior version of Rule 10b5-1(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.